Publisher： Bentham Science Publishers
E-ISSN： 1873-4286|19|5|940-950
ISSN： 1381-6128
Source： Current Pharmaceutical Design, Vol.19, Iss.5, 2013-02, pp. : 940-950
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Development of c-MET pathway inhibitors
By Liu Xiangdong Newton Robert C Scherle Peggy A
Expert Opinion on Investigational Drugs, Vol. 20, Iss. 9, 2011-09 ,pp. :
Access to resources
Recommend
Gemcitabine plus docetaxel `has moderate activity' in advanced pancreatic cancer
Inpharma, Vol. 1, Iss. 1281, 2001-01 ,pp. :
By Varkaris Andreas Corn Paul G Gaur Sanchaika Dayyani Farshid Logothetis Christopher J Gallick Gary E
Expert Opinion on Investigational Drugs, Vol. 20, Iss. 12, 2011-12 ,pp. :
Erlotinib + gemcitabine of no value in pancreatic cancer
Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. :
Erlotinib + gemcitabine of no value in pancreatic cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 539, 2007-01 ,pp. :